Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Disufenton_sodium> ?p ?o. }
Showing items 1 to 50 of
50
with 100 items per page.
- Disufenton_sodium abstract "Disufenton sodium (NXY-059, Cerovive) is the disulfonyl derivative of the neuroprotective spin trap phenylbutynitrone or "PBN". It was under development at the drug company AstraZeneca. A 2005 phase-3 clinical trial called "SAINT-1" reported some efficacy in the acute treatment of ischemia injury due to stroke. However, a 2006 attempt to repeat this trial indicated no significant activity. After ruling out other causes, the authors tentatively attributed the positive results in the first trial to "chance". AstraZeneca then terminated the development programme. PBN and its derivatives hydrolyze and oxidize in vitro to form respectively MNP-OH ( AKA, NtBHA ) and its parent spin-trap MNP.".
- Disufenton_sodium atcPrefix "none".
- Disufenton_sodium fdaUniiCode "7M1J3HN9VO".
- Disufenton_sodium iupacName "Disodium 4-[(Z)-(tert-butyl-oxidoazaniumylidene)methyl]benzene-1,3-disulfonate".
- Disufenton_sodium pubchem "6440181".
- Disufenton_sodium thumbnail Disufenton_sodium.png?width=300.
- Disufenton_sodium wikiPageExternalLink 3221.
- Disufenton_sodium wikiPageExternalLink 461.
- Disufenton_sodium wikiPageID "6826044".
- Disufenton_sodium wikiPageRevisionID "588068841".
- Disufenton_sodium atcPrefix "none".
- Disufenton_sodium c "11".
- Disufenton_sodium chembl "1627056".
- Disufenton_sodium h "13".
- Disufenton_sodium hasPhotoCollection Disufenton_sodium.
- Disufenton_sodium iupacName "Disodium 4-[-methyl]benzene-1,3-disulfonate".
- Disufenton_sodium kegg "D03875".
- Disufenton_sodium molecularWeight "381.33".
- Disufenton_sodium n "1".
- Disufenton_sodium na "2".
- Disufenton_sodium o "7".
- Disufenton_sodium pubchem "6440181".
- Disufenton_sodium s "2".
- Disufenton_sodium unii "7".
- Disufenton_sodium verifiedfields "changed".
- Disufenton_sodium verifiedrevid "405853279".
- Disufenton_sodium watchedfields "changed".
- Disufenton_sodium subject Category:AstraZeneca.
- Disufenton_sodium subject Category:Free_radicals.
- Disufenton_sodium type Abstraction100002137.
- Disufenton_sodium type Atom114619225.
- Disufenton_sodium type FreeRadical114874196.
- Disufenton_sodium type FreeRadicals.
- Disufenton_sodium type Matter100020827.
- Disufenton_sodium type Part113809207.
- Disufenton_sodium type PhysicalEntity100001930.
- Disufenton_sodium type Relation100031921.
- Disufenton_sodium type Substance100019613.
- Disufenton_sodium type Drug.
- Disufenton_sodium type DrugProduct.
- Disufenton_sodium type FunctionalSubstance.
- Disufenton_sodium comment "Disufenton sodium (NXY-059, Cerovive) is the disulfonyl derivative of the neuroprotective spin trap phenylbutynitrone or "PBN". It was under development at the drug company AstraZeneca. A 2005 phase-3 clinical trial called "SAINT-1" reported some efficacy in the acute treatment of ischemia injury due to stroke. However, a 2006 attempt to repeat this trial indicated no significant activity.".
- Disufenton_sodium label "Disufenton sodium".
- Disufenton_sodium sameAs m.0gr4yy.
- Disufenton_sodium sameAs Q5283598.
- Disufenton_sodium sameAs Q5283598.
- Disufenton_sodium sameAs Disufenton_sodium.
- Disufenton_sodium wasDerivedFrom Disufenton_sodium?oldid=588068841.
- Disufenton_sodium depiction Disufenton_sodium.png.
- Disufenton_sodium isPrimaryTopicOf Disufenton_sodium.